巨细胞病毒再激活对异基因造血干细胞移植术后免疫功能的影响  

Effect of cytomegalovirus reactivation on immune function after allogeneic hematopoietic stem cell transplantation

作　　者：柳丽娟 刘秀丽 袁海龙[1] LIU Lijuan;LIU Xiuli;YUAN Hailong(Department of Hematology,The First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang Uygur Autonomous Region,Urumqi,Xinjiang 830000,China)

机构地区：[1]新疆医科大学第一附属医院血液科,新疆乌鲁木齐830000

出　　处：《现代医药卫生》2025年第2期506-511,共6页Journal of Modern Medicine & Health

摘　　要：巨细胞病毒(CMV)是一种在世界范围内广泛感染的病毒。在免疫正常的个体中,CMV通常是潜伏的,而在免疫缺陷的个体中感染或再激活可导致严重的临床症状甚至死亡。异基因造血干细胞移植术(allo-HSCT)后患者免疫功能尚未恢复,CMV导致移植物植入不良及引起巨细胞病毒血症及巨细胞病毒病,是移植后非复发死亡的主要因素,而细胞介导的免疫反应是控制CMV感染和复制的主要因素,T细胞受体(TCR)在T细胞免疫应答中不可或缺的作用。TCR对开发新的诊断和预后方法,以及对临床CMV感染患者监测和管理的影响将是深远的。TCR序列检测与研究将有助于评估疫苗疗效、免疫治疗策略和CMV感染的早期诊断。该文对CMV发生后对移植后患者免疫功能影响作一综述,以期对allo-ASCT后CMV发生、治疗及预防方面提供思路。Cytomegalovirus(CMV)is a virus that is widely prevalent worldwide.In individuals with normal immunity,CMV is typically latent,while in immunocompromised individuals,infection or reactivation can lead to severe clinical symptoms and even death.After allogeneic hematopoietic stem cell transplantation(allo-HSCT),patients have not yet fully recovered their immune function.CMV infection can result in poor graft implantation,cytomegalovirus viremia,and CMV disease,which are major causes of non-relapse mortality post-transplantation.Cell-mediated immune responses are the key factors in controlling CMV infection and replication,and T-cell receptors(TCRs)play an indispensable role in T-cell immune responses.The impact of TCRs on the development of new diagnostic and prognostic methods,as well as on monitoring and managing clinical CMV infections,will be profound.TCR sequence detection and research will contribute to evaluating vaccine efficacy,immunotherapy strategies,and the early diagnosis of CMV infections.This review discusses the effects of CMV infection on immune function in transplant patients,aiming to provide insights for CMV occurrence,treatment,and prevention after allo-HSCT.

关 键 词：ALLO-HSCT CMV 免疫功能 TCR 综述 

分 类 号：R392[医药卫生—免疫学]